CANSINOBIO (06185) Sets 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal

Bulletin Express

Mar 17

CanSino Biologics Inc. (stock code: 06185) has announced that its board of directors will convene on 30 March 2026 to review and approve the consolidated financial results for the year ended 31 December 2025. The agenda also includes deliberation on a potential final dividend recommendation for shareholders.

The notice, dated 17 March 2026, was signed by Chairman Dr. Xuefeng Yu. As at the date of the announcement, the Board comprises three executive directors (Dr. Xuefeng Yu, Dr. Shou Bai Chao and Ms. Jing Wang), one non-executive director (Mr. Chi Shing Li) and three independent non-executive directors (Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji).

Further details on the company’s FY 2025 performance and any proposed dividend will be released following the Board’s deliberations on 30 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1174974454"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174974454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174974454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174974454","market":"us","top_or_hot":-1,"title":"CANSINOBIO (06185) Sets 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (stock code: 06185) has announced that its board of directors will convene on 30 March 2026 to review and approve the consolidated financial results for the year ended 31 December 2025. The agenda also includes deliberation on a potential final dividend recommendation for shareholders.</p>\n<p>The notice, dated 17 March 2026, was signed by Chairman Dr. Xuefeng Yu. As at the date of the announcement, the Board comprises three executive directors (Dr. Xuefeng Yu, Dr. Shou Bai Chao and Ms. Jing Wang), one non-executive director (Mr. Chi Shing Li) and three independent non-executive directors (Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji).</p>\n<p>Further details on the company’s FY 2025 performance and any proposed dividend will be released following the Board’s deliberations on 30 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO (06185) Sets 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO (06185) Sets 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-17 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (stock code: 06185) has announced that its board of directors will convene on 30 March 2026 to review and approve the consolidated financial results for the year ended 31 December 2025. The agenda also includes deliberation on a potential final dividend recommendation for shareholders.</p>\n<p>The notice, dated 17 March 2026, was signed by Chairman Dr. Xuefeng Yu. As at the date of the announcement, the Board comprises three executive directors (Dr. Xuefeng Yu, Dr. Shou Bai Chao and Ms. Jing Wang), one non-executive director (Mr. Chi Shing Li) and three independent non-executive directors (Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji).</p>\n<p>Further details on the company’s FY 2025 performance and any proposed dividend will be released following the Board’s deliberations on 30 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1174974454","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174974454","pubTimestamp":1773736881,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (stock code: 06185) has announced that its board of directors will convene on 30 March 2026 to review and approve the consolidated financial results for the year ended 31...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物(06185)定于2026年3月30日召开董事会批准2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (stock code: 06185) has announced that its board of directors will convene on 30 March 2026 to review and approve the consolidated financial results for the year ended 31 December 2025. The agenda also includes deliberation on a potential final dividend recommendation for shareholders.\nThe notice, dated 17 March 2026, was signed by Chairman Dr. Xuefeng Yu. As at the date of the announcement, the Board comprises three executive directors (Dr. Xuefeng Yu, Dr. Shou Bai Chao and Ms. Jing Wang), one non-executive director (Mr. Chi Shing Li) and three independent non-executive directors (Mr. Yiu Leung Andy Cheung, Mr. Man Cho and Ms. Xuefeng Ji).\nFurther details on the company’s FY 2025 performance and any proposed dividend will be released following the Board’s deliberations on 30 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}